Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Pharmacol.

Sec. Pharmacogenetics and Pharmacogenomics

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1660719

Higher Prevalence of NUDT15 rs116855232 Compared to TPMT rs1142345 in a Chinese Cohort and Its Implications for Thiopurine Therapy

Provisionally accepted
  • 1Henan Provincial People's Hospital, Zhengzhou, China
  • 2Department of Medical Genetics, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410013, China, Changsha, China

The final, formatted version of the article will be published soon.

Background: Thiopurine drugs are widely used as immunosuppressants and chemotherapeutic agents in clinical practice, but their adverse effects significantly limit their clinical application. TPMT c.719A>G (rs1142345) and NUDT15 c.415C>T (rs116855232) are the most common genetic polymorphisms influencing thiopurine drug toxicity, with notable differences in allele frequencies across diverse populations. However, there remains a paucity of research on the NUDT15 c.415C>T polymorphism in the Chinese population. Methods: This study enrolled 571 Chinese patients. DNA samples were isolated, and polymerase chain reaction (PCR) was performed to amplify the TPMT c.719A>G and NUDT15 c.415C>T in each sample. PCR products were genotyped via Sanger sequencing to identify the allelic frequencies of these polymorphisms. Additionally, we compared the detection rate of NUDT15 c.415C>T and TPMT c.719A>G for thiopurine drug toxicity in the cohort. Results: The minor allele frequencies of NUDT15 c.415C>T and TPMT c.719A>G were determined to be 12.52% and 2.36%, respectively. The detection rate of the NUDT15 c.415C>T polymorphism was significantly higher than that of TPMT c.719A>G (23.47% vs. 4.55%, P < 0.001). Conclusions: NUDT15 c.415C>T yielded a higher carrier rate than TPMT c.719A>G in this cohort. And broader panels could shift absolute yields. These findings highlight the critical role of NUDT15 c.415C>T genotyping in guiding precision therapy with thiopurine drugs.

Keywords: NUDT15, TPMT, Thiopurine, gene polymorphism, Pharmacogenetics

Received: 06 Jul 2025; Accepted: 20 Aug 2025.

Copyright: © 2025 Zhao and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Chenyu Zhao, Henan Provincial People's Hospital, Zhengzhou, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.